Business Context and Reporting Period
This Form 10-Q covers Eli Lilly and Company for the quarter and six months ended June 30, 1999. The company operates primarily in pharmaceutical products, with animal health operations deemed immaterial. A significant event during the period was the January 1999 sale of its PCS health-care-management subsidiary to Rite Aid Corporation for $1.60 billion, classified as discontinued operations.
Key Financial Metrics
| Metric (Six Months Ended June 30, 1999) | Value ($ Millions) |
|---|---|
| Net Sales | 4,597.2 |
| Net Income | 1,202.1 |
| Income from Continuing Operations | 1,027.8 |
| Diluted EPS (Net Income) | $1.08 |
| Gross Margin | 78.6% |
| Operating Cash Flow | 607.1 |
| Cash and Cash Equivalents (June 30, 1999) | 2,031.7 |
| Total Debt (Short-term + Long-term) | 2,337.8 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% year-over-year for the six-month period, driven by volume growth of 9% and new product launches (Zyprexa, Gemzar, ReoPro, Evista). This offset declines in anti-infectives and Axid sales.
- Profitability: Net income rose 19% to $1.20 billion. Excluding non-recurring items (PCS sale gain, asset impairment, foundation funding charge), net income from continuing operations increased 15%.
- Discontinued Operations: The sale of PCS generated a $174.3 million gain, net of tax, in the first quarter.
- Special Charges: The six-month period included a $61.4 million asset impairment charge for manufacturing assets and a $150.0 million pre-tax charge for funding commitments to the Eli Lilly and Company Foundation.
- Expenses: R&D expenses increased 12% to $873.6 million. Marketing and administrative expenses rose 5% due to new product launches and Y2K readiness efforts.
Guidance, Outlook, and Risks
- Product Outlook: Management anticipates slight growth in worldwide Prozac sales for the full year, contingent on marketing effectiveness against generic competition. Zyprexa is expected to continue strong growth, though at a lower percentage than 1998. Evista sales are projected to remain strong.
- Capital Allocation: The board expanded the 1999 share repurchase program from $1.0 billion to $1.5 billion. The company issued $825 million in new debt in August 1999 for general corporate purposes.
- Legal Contingencies: Significant litigation involves generic challenges to Prozac patents (Barr, Geneva, Zenith, Teva, Cheminor, Novex). An unfavorable outcome could materially affect financial position. Product liability suits regarding diethylstilbestrol and Prozac are ongoing, with accruals of approximately $284.4 million (gross) and estimated insurance recoverables of $227.1 million.
- Y2K and Euro: The company estimates total Y2K costs between $160 million and $180 million, with 75-80% incurred by June 30, 1999. Euro conversion compliance is underway with no expected material cost impact.
Investor Verification Checklist
- Verify the status and potential financial impact of the Prozac patent litigation against six generic manufacturers.
- Confirm the timeline and cost estimates for the completion of Y2K remediation for critical IT and non-IT systems.
- Monitor the execution of the expanded $1.5 billion share repurchase program.
- Assess the sustainability of sales growth for Zyprexa and Evista against competitive pressures in the antidepressant and osteoporosis markets.
- Review the resolution of the $150 million foundation funding charge and its impact on future charitable contribution accounting.